See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Xianglei He
Zhejiang Provincial People's Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-7685-3451
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Angiogenic factor with G-patch and FHA domains 1 (AGGF1) can promote angiogenesis and increasing evidence has highlighted the important roles of AGGF1 in tumorigenesis. However, the differential expression as well as the biological functions of AGGF1 in colorectal cancer (CRC) remain to be established. The purpose of the present study is therefore to identify the effect of AGGF1 on prognosis and metastasis in CRC patients. Methods: The expression level of AGGF1 in CRC was examined by qPCR, western blot and immunohistochemistry in a tissue microarray containing 101 CRC specimens and paired normal mucosae. And the effect of AGGF1 on CRC cell malignance was investigated in our established stable AGGF1 upregulated and knockdown CRC cell lines. Results: The expression level of AGGF1 in CRC tissue was not significantly different to that in adjacent normal mucosa at the mRNA level. However, at the protein level, AGGF1 expression in CRC tissues was significantly higher than in paired normal mucosa, which showed a clear association with TNM stage, AJCC stage, vascular invasion, and differentiation. Further, we revealed an apparent correlation between AGGF1 expression and poorer disease-free survival and overall survival of CRC patients. In addition, we discovered that AGGF1 significantly promoted CRC cell wound healing, migration, and invasion in vitro and distant metastasis in vivo. Conclusions: Our study demonstrates the aberrant expression of AGGF1 in CRC and provides a basis on which to explore the application of AGGF1 as a novel prognostic biomarker as well as a therapeutic target for CRC patients, especially for CRC patients with distant metastasis.
Keywords
Colorectal cancer; AGGF1; Prognosis; Metastasis
Figure 1
Figure 2
Figure 3
This is a list of supplementary files associated with this preprint. Click to download.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Submission checks complete
On 17 Dec, 2019
Editorial decision: Accept
On 17 Dec, 2019
No comments provided
Editorial decision: Minor revision
On 12 Dec, 2019
Editor assigned
On 10 Dec, 2019
Submission checks complete
On 09 Dec, 2019
Editor invited
On 09 Dec, 2019
Version 3
Posted 02 Dec, 2019
No comments provided
Editorial decision: Minor revision
On 05 Dec, 2019
Review #1 received
Received 04 Dec, 2019
Reviewer #2 agreed
On 22 Nov, 2019
Reviewers invited
Invitations sent on 21 Nov, 2019
Reviewer #1 agreed
On 21 Nov, 2019
Editor assigned
On 20 Nov, 2019
Submission checks complete
On 19 Nov, 2019
Editor invited
On 19 Nov, 2019
No comments provided
Editorial decision: Minor revision
On 06 Nov, 2019
Reviewer #3 agreed
On 27 Oct, 2019
Reviewer #2 agreed
On 25 Oct, 2019
Reviewer #1 agreed
On 23 Oct, 2019
Reviewers invited
Invitations sent on 22 Oct, 2019
Editor assigned
On 21 Oct, 2019
Submission checks complete
On 20 Oct, 2019
Editor invited
On 20 Oct, 2019
No comments provided
Editorial decision: Major revision
On 03 Oct, 2019
Review #3 received
Received 02 Oct, 2019
Review #2 received
Received 26 Sep, 2019
Review #1 received
Received 26 Sep, 2019
Reviewer #3 agreed
On 14 Sep, 2019
Reviewer #2 agreed
On 13 Sep, 2019
Submission checks complete
On 10 Sep, 2019
Editor invited
On 10 Sep, 2019
Editor assigned
On 10 Sep, 2019
Reviewers invited
Invitations sent on 10 Sep, 2019
Reviewer #1 agreed
On 10 Sep, 2019
First submitted
On 28 Aug, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Xianglei He
Zhejiang Provincial People's Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0002-7685-3451
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Submission checks complete
On 17 Dec, 2019
Editorial decision: Accept
On 17 Dec, 2019
No comments provided
Editorial decision: Minor revision
On 12 Dec, 2019
Editor assigned
On 10 Dec, 2019
Submission checks complete
On 09 Dec, 2019
Editor invited
On 09 Dec, 2019
Version 3
Posted 02 Dec, 2019
No comments provided
Editorial decision: Minor revision
On 05 Dec, 2019
Review #1 received
Received 04 Dec, 2019
Reviewer #2 agreed
On 22 Nov, 2019
Reviewers invited
Invitations sent on 21 Nov, 2019
Reviewer #1 agreed
On 21 Nov, 2019
Editor assigned
On 20 Nov, 2019
Submission checks complete
On 19 Nov, 2019
Editor invited
On 19 Nov, 2019
No comments provided
Editorial decision: Minor revision
On 06 Nov, 2019
Reviewer #3 agreed
On 27 Oct, 2019
Reviewer #2 agreed
On 25 Oct, 2019
Reviewer #1 agreed
On 23 Oct, 2019
Reviewers invited
Invitations sent on 22 Oct, 2019
Editor assigned
On 21 Oct, 2019
Submission checks complete
On 20 Oct, 2019
Editor invited
On 20 Oct, 2019
No comments provided
Editorial decision: Major revision
On 03 Oct, 2019
Review #3 received
Received 02 Oct, 2019
Review #2 received
Received 26 Sep, 2019
Review #1 received
Received 26 Sep, 2019
Reviewer #3 agreed
On 14 Sep, 2019
Reviewer #2 agreed
On 13 Sep, 2019
Submission checks complete
On 10 Sep, 2019
Editor invited
On 10 Sep, 2019
Editor assigned
On 10 Sep, 2019
Reviewers invited
Invitations sent on 10 Sep, 2019
Reviewer #1 agreed
On 10 Sep, 2019
First submitted
On 28 Aug, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Background: Angiogenic factor with G-patch and FHA domains 1 (AGGF1) can promote angiogenesis and increasing evidence has highlighted the important roles of AGGF1 in tumorigenesis. However, the differential expression as well as the biological functions of AGGF1 in colorectal cancer (CRC) remain to be established. The purpose of the present study is therefore to identify the effect of AGGF1 on prognosis and metastasis in CRC patients. Methods: The expression level of AGGF1 in CRC was examined by qPCR, western blot and immunohistochemistry in a tissue microarray containing 101 CRC specimens and paired normal mucosae. And the effect of AGGF1 on CRC cell malignance was investigated in our established stable AGGF1 upregulated and knockdown CRC cell lines. Results: The expression level of AGGF1 in CRC tissue was not significantly different to that in adjacent normal mucosa at the mRNA level. However, at the protein level, AGGF1 expression in CRC tissues was significantly higher than in paired normal mucosa, which showed a clear association with TNM stage, AJCC stage, vascular invasion, and differentiation. Further, we revealed an apparent correlation between AGGF1 expression and poorer disease-free survival and overall survival of CRC patients. In addition, we discovered that AGGF1 significantly promoted CRC cell wound healing, migration, and invasion in vitro and distant metastasis in vivo. Conclusions: Our study demonstrates the aberrant expression of AGGF1 in CRC and provides a basis on which to explore the application of AGGF1 as a novel prognostic biomarker as well as a therapeutic target for CRC patients, especially for CRC patients with distant metastasis.
Figure 1
Figure 2
Figure 3
This is a list of supplementary files associated with this preprint. Click to download.
Loading...